Ensign Group (ENSG) is back in focus after reporting second quarter 2026 adjusted EPS of US$1.92, beating estimates, lifting its full year revenue and EPS outlook, and pairing results with buybacks and dividends.

Ensign Group’s latest results land after a volatile few months for the stock, with recent short seller allegations and securities investigations triggering sharp swings and a share price of US$173.54 that is down over the past month but still higher on a 90 day share price return basis. While near term momentum has faded, the modest 1 year total shareholder return and much stronger 3 and 5 year total shareholder returns point to a story in which long term holders have experienced materially better outcomes than recent traders.

Spot potential peers to Ensign Group with resilient growth stories by scanning our hand picked 20 high quality undiscovered gems in the healthcare and broader market space.

After a sharp pullback but still solid multi year gains, Ensign Group now asks you to weigh stronger earnings and a higher outlook against regulatory and short seller risk. Does that balance still favour buyers at US$173.54?

Preferred P/E of 26.5x: Is it justified for Ensign Group?

At a last close of $173.54, Ensign Group is priced on a P/E of 26.5x, which screens as expensive both versus peers and versus its own fair P/E estimate.

The P/E ratio compares the share price to earnings per share and is a simple way to see how much investors are paying for each dollar of current earnings. For Ensign Group, the current 26.5x P/E aligns with a business that has grown earnings by 14.2% per year over the past 5 years and is forecast to grow earnings by 12.82% per year, but it also means the stock is not cheap on this metric.

Against this backdrop, the P/E of 26.5x sits above the US Healthcare industry average of 25.6x and above the estimated fair P/E of 26x. That points to a premium that the market is currently paying versus both sector peers and the level that regression based fair value work suggests the multiple could move toward over time.

Explore the SWS fair ratio for Ensign Group.

Result: Price-to-Earnings of 26.5x (OVERVALUED)

However, the short seller allegations, ongoing securities investigations, and any change in Ensign Group’s regulatory environment could quickly challenge the current premium P/E narrative.

Another view on Ensign Group’s value

The P/E work suggests Ensign Group screens as slightly expensive, yet our DCF model points in the opposite direction. With the stock at $173.54 and our future cash flow value estimate at $198.98, the shares screen as about 12.8% undervalued on this approach. Which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of concerns and optimism around Ensign Group, it makes sense to check the underlying drivers yourself and move quickly to form a view. To see what has investors encouraged, start with the 4 key rewards.

Looking for more investment ideas beyond Ensign Group?

If you stop at Ensign Group, you may miss stocks that better fit your goals, risk comfort, and income needs. Put the Simply Wall Street Screener to work.

• Target potential mispriced opportunities by focusing on quality companies with room for a re rating through the 46 high quality undervalued stocks.
• Strengthen your focus on resilience by filtering for companies with healthier finances using the list of solid balance sheet and fundamentals (50 results).
• Build potential income streams by finding companies that offer higher yields through the 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.